DeBinge Let's talk
DeBinge Clinical Education

When Addiction Treatment Says No: Your Guide to Finding Appropriate Opioid Recovery Care

Being refused admission to an addiction treatment programme can be devastating, particularly when you are already receiving methadone or buprenorphine and are trying to make an informed decision about your recovery.

Some rehabilitation programmes have restrictive medication policies. Others lack the clinical facilities to manage complex withdrawal or a transition to naltrexone. These barriers can leave patients feeling that they have nowhere to turn.

However, a refusal from one provider does not mean that effective treatment is unavailable. Understanding why the refusal occurred, what evidence-based alternatives exist and how to obtain a suitable assessment can help patients move forward safely.

Quick answer: What should you do after a treatment refusal?

Ask the provider to explain its decision, confirm whether the issue is clinical or administrative and request a referral to an appropriate service.

Do not discontinue methadone, buprenorphine or other prescribed medication simply to satisfy a rehabilitation centre’s admission policy.

If you are interested in transitioning to naltrexone, consult an addiction specialist about the medical requirements and potential risks before making changes.

Clinical Governance

Medically Reviewed

Dr Fergus Law, BSc, MBChB, FRCPsych

Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.

This article is prepared for clinical review and should not be presented as medically approved until a qualified clinician has evaluated its discussion of medication transitions, admission restrictions, contraindications and treatment risks.

Dr Fergus Law’s Professional Profile

Review status: Medically reviewed by Dr Fergus Law on 15 October 2026 clinical approval.
Section 1

Why Getting Addiction Treatment Can Be Harder Than Expected

Seeking treatment for opioid use disorder is a significant decision. Many people have already experienced unsuccessful attempts to stop using opioids, periods of withdrawal, difficult relationships with healthcare providers or concerns about stigma.

When an addiction treatment centre then refuses admission, the individual may interpret the decision as a message that treatment is impossible.

This conclusion is not necessarily correct. Addiction treatment services differ in the populations they accept, the medications they provide and the complexity of care they can safely deliver.

Common reasons for admission difficulties

Medication policies

Some residential programmes do not provide ongoing methadone or buprenorphine treatment or have policies restricting certain medications.

These restrictions do not mean that maintenance treatment is ineffective or that the patient must discontinue medication to pursue recovery.

Medical capabilities

A rehabilitation facility may lack the staff, equipment or prescribing arrangements necessary to manage complicated withdrawal or significant medical illness.

Psychiatric needs

Patients experiencing acute mental-health crises or requiring specialist psychiatric supervision may need services beyond a particular centre’s capability.

Administrative restrictions

Availability, insurance arrangements, payment requirements, residency criteria and age-specific programmes can also affect admission.

Why medication restrictions deserve careful examination

Methadone and buprenorphine have strong evidence supporting their effectiveness in treating opioid use disorder. They are associated with important reductions in overdose and mortality risk when used appropriately.

A programme that cannot accommodate these treatments should clearly explain its capabilities and provide appropriate referral options.

Example: A patient taking methadone

A patient has received methadone treatment for two years and has stopped using illicit opioids. They apply to a residential rehabilitation centre seeking additional counselling and psychological support.

The centre says patients must discontinue methadone before admission.

Rather than immediately stopping medication, the patient should ask whether the centre can coordinate with the existing prescriber or refer them to a service that supports medication treatment.

The important question is whether changing medication offers a genuine clinical advantage, not whether it satisfies a facility’s preferred treatment philosophy.

What should you do first?

  1. Ask why the application was declined.
  2. Request the admission policy or relevant criteria in writing.
  3. Ask whether the decision was made by a qualified clinician.
  4. Discuss any proposed medication changes with your current prescriber.
  5. Request a referral to an appropriate alternative.
  6. Arrange another assessment if the original provider cannot help.
Back to top ↑
Section 2

Is a Refusal a Clinical Decision or Unfair Exclusion?

There is an important distinction between a facility explaining that it lacks the clinical resources to treat someone safely and a facility imposing restrictions that may be inconsistent with evidence-based care or applicable anti-discrimination requirements.

Not every refusal is unlawful discrimination. However, patients deserve an explanation that allows them to understand whether the decision relates to clinical needs, programme rules or administrative factors.

What may be a legitimate clinical limitation?

A centre without hospital-level medical support may determine that a patient with serious unstable illness needs a more intensive medical setting.

Similarly, a programme without appropriate psychiatric services may need to arrange specialist treatment for someone experiencing an acute psychiatric emergency.

These decisions should be based on individual needs rather than unsupported assumptions about the person.

What should raise further questions?

  • A blanket statement that taking prescribed methadone means the person is not in recovery.
  • A refusal without a meaningful explanation of the admission criteria.
  • Pressure to discontinue clinically beneficial medication without coordination with the prescriber.
  • Different treatment of comparable applicants without a clear clinical justification.
  • No referral or reasonable information about alternative services.

Could disability protections apply?

In the United States, some people receiving medication treatment for opioid use disorder may be protected under disability laws, depending on the circumstances.

Whether a particular refusal is discriminatory depends on factors including the provider, the person’s current circumstances, the reason for exclusion and applicable federal or state law.

A patient who believes discrimination occurred can ask the provider for its written policy and seek advice from an appropriate patient advocate or legal professional.

Example: Requesting clarification respectfully

“I understand that your programme may have clinical limitations. Could you explain whether your decision is based on my medical needs, your medication policy or another admission criterion?”

“I am receiving prescribed treatment from a qualified clinician. Is there a process for an individual clinical review, or could you refer me to a programme that can support my current medication?”

Do not turn a policy dispute into a medical emergency

Even if a patient believes a provider’s rule is unreasonable, abruptly stopping prescribed medication can expose them to withdrawal, destabilisation and increased overdose risk.

Continue coordinating treatment with the existing prescriber while investigating other options.

Back to top ↑
Section 3

Evidence-Based Treatment: Understanding Your Medication Options

Effective treatment for opioid use disorder can involve medication, clinical monitoring, counselling and practical support. The appropriate combination depends on individual circumstances.

Methadone

Methadone is a long-acting full opioid agonist that reduces withdrawal symptoms and cravings. It is a well-established treatment for opioid use disorder and can be continued for an extended period when clinically appropriate.

Someone who is stable on methadone should not assume that stopping it is necessary to achieve meaningful recovery.

Buprenorphine

Buprenorphine is a partial opioid agonist that can reduce cravings and withdrawal symptoms while supporting ongoing treatment.

It is available through appropriately authorised healthcare professionals and may be suitable for long-term treatment.

Naltrexone

Naltrexone is an opioid antagonist that blocks opioid receptor activity. It can be considered for certain patients who wish to pursue an antagonist-based treatment approach.

Because naltrexone can precipitate withdrawal when introduced during opioid dependence, it requires careful assessment and appropriate induction.

How these options compare

Agonist treatment

Methadone and buprenorphine

Can reduce withdrawal and cravings through opioid receptor activity. Both have substantial evidence supporting their use and may remain appropriate long-term.

Antagonist treatment

Naltrexone

Blocks opioid receptor activity. Requires medically appropriate initiation and may suit selected people who prefer this approach after reviewing alternatives.

Safety warning: Naltrexone induction

Administering naltrexone while a person remains physically dependent on opioids can cause severe precipitated withdrawal.

An expedited transition should only be managed by appropriately experienced clinicians. A provider’s statement that patients can arrive without completing an opioid-free period is not a guarantee that naltrexone can safely be administered immediately.

How should patients decide?

The decision should consider current medication effectiveness, previous experiences, physical health, mental health, relapse and overdose risk, treatment availability and personal preferences.

Patients should be offered an honest discussion of the benefits and limitations of each appropriate option.

Back to top ↑
Section 4

Why Moving From Methadone to Naltrexone Requires Particular Care

Methadone is a long-acting opioid medication. People taking it regularly may have substantial physical dependence, even when their use is stable and medically supervised.

A transition to naltrexone is not simply a matter of replacing one medication with another. The medications work in fundamentally different ways.

What happens if methadone is stopped abruptly?

Withdrawal may include gastrointestinal symptoms, insomnia, anxiety, muscle pain, restlessness and strong cravings.

For some patients, abrupt discontinuation may lead to resumed opioid use, destabilisation or other complications.

Why is naltrexone different?

Unlike methadone, naltrexone does not provide opioid agonist activity. If it is introduced too soon, it may trigger precipitated withdrawal.

For this reason, a transition must be individually planned and supervised.

What does the ASAM guidance emphasise?

ASAM guidance highlights that changing from methadone to naltrexone requires careful withdrawal management and clinical oversight.

An experienced clinician may consider specialised strategies in appropriately selected patients, but these should not be confused with a simple or universally safe rapid switch.

Example: A patient considering a change

A patient has been taking methadone for three years and wants to become free of opioid agonist medication.

Before pursuing naltrexone, their clinician should review how well methadone is working, the reasons for wanting a change, previous withdrawal experiences, the risks of discontinuation and alternative approaches.

The patient might decide to remain on methadone or pursue a supervised transition after a comprehensive assessment.

Five important questions

  1. What are the clinical advantages of changing my current treatment?
  2. Could discontinuation increase my risk of returning to opioid use?
  3. What withdrawal symptoms might occur?
  4. How will the team determine readiness for naltrexone?
  5. What happens if the planned transition cannot proceed safely?
Back to top ↑
Section 5

What a Proper Addiction Treatment Assessment Should Include

An effective assessment is more than a brief admissions questionnaire. It should help determine whether a particular service can safely meet the patient’s clinical needs.

1. Medication and substance history

The clinical team should obtain information about prescribed medications, recent opioid use, other substances, previous medication treatments and relevant withdrawal experiences.

2. Physical health

Assessment may include medical history, relevant examinations, medication interactions, pain conditions, pregnancy considerations where relevant and other factors that influence treatment safety.

3. Mental health

The team should review relevant psychiatric symptoms, previous diagnoses, treatment history and immediate concerns requiring specialist support.

4. Previous treatment outcomes

Someone who has repeatedly returned to opioid use after unsupported withdrawal may need a different treatment strategy from someone who has been stable on maintenance medication.

5. Treatment preferences

Patients should be able to explain their goals and concerns. A person may wish to remain on methadone, explore buprenorphine or consider antagonist treatment.

6. Follow-up and continuity

An assessment should consider what will happen after the initial treatment period, including medication management, counselling and appropriate care in the patient’s home community.

Example: How to prepare for an assessment

Write down your current medications and doses, substance use history, previous withdrawal experiences, other medical conditions, questions about treatment and the support you will need after admission.

Be accurate rather than trying to provide what you think the clinic wants to hear.

What if a clinic cannot meet your needs?

Ask whether it can recommend an appropriate specialist provider or coordinate a referral.

A well-explained referral may be more helpful than admission to a facility that is not equipped to provide safe treatment.

Back to top ↑
Section 6

Can Opioid Withdrawal Be Managed Without Unnecessary Suffering?

Withdrawal can be physically and psychologically distressing. Symptoms vary according to the medication or substance involved, the degree of dependence and the individual’s health.

Medical treatment can help manage withdrawal and reduce unnecessary distress, but no reputable programme should guarantee a painless experience.

What does supervised care involve?

  • Assessment of physical dependence and relevant medical risks.
  • Selection of an appropriate treatment strategy.
  • Monitoring withdrawal symptoms and other complications.
  • Clinical responses when symptoms become more severe.
  • Reassessment of the plan when necessary.
  • Preparation for ongoing care rather than withdrawal management alone.

Why withdrawal management alone is not enough

Completing withdrawal does not automatically resolve opioid use disorder. A person may continue to experience cravings, social triggers, anxiety, depression or other circumstances that increase the risk of returning to opioid use.

Tolerance can also decline after stopping opioids, increasing overdose vulnerability if previous doses are resumed.

Important

Do not stop methadone, buprenorphine or other prescribed medication based on general online advice.

Any change should be discussed with the prescribing clinician and planned with appropriate monitoring and support.

What should you ask a prospective provider?

Ask what symptoms are expected, how they are monitored, who is responsible for treatment decisions, what emergency arrangements exist and what happens if the patient cannot proceed with the planned transition.

Back to top ↑
Section 7

What Private Medical and Nursing Support Can Contribute

Private treatment may offer more individual attention and a quieter environment. Some patients value discretion, reduced distractions and the opportunity to discuss sensitive circumstances directly with clinicians.

However, private accommodation and personalised attention cannot replace appropriate medical facilities, clinical expertise or emergency services.

What can a private doctor contribute?

A physician can evaluate medical history, identify contraindications, review treatment alternatives, oversee clinical decisions and respond to changes in a patient’s medical condition.

Patients should ask who the responsible doctor is, what qualifications and experience they hold and when they are available.

What can dedicated nursing support contribute?

Qualified nursing staff may monitor symptoms, observe a patient’s clinical condition, administer prescribed care within their professional scope and communicate relevant changes to the physician.

Nursing support is valuable, but the actual level of coverage should be established rather than assumed.

Does privacy make treatment safer?

Privacy may improve comfort, confidentiality and willingness to discuss personal concerns. Safety, however, depends primarily on the treatment plan, the professionals involved, monitoring and access to appropriate medical care.

Example questions about private care

“Will I have a named treating physician? What nursing coverage is available, including overnight? Which observations will be performed, and how would you arrange emergency hospital treatment?”

Do not assume exclusive accommodation

If a programme advertises private accommodation, request written confirmation of what is included.

Ask whether rooms or accommodation are shared, what facilities are provided and whether any additional charges apply.

Back to top ↑
Section 8

Mental Health, Family Responsibilities and Continuing Support

Addiction treatment planning should recognise that people have responsibilities, relationships, emotional needs and practical circumstances outside the treatment facility.

Mental-health assessment

Depression, anxiety, trauma-related symptoms and other psychiatric difficulties can influence treatment needs.

A programme should explain which mental-health services it can provide and when specialist assessment or referral is necessary.

What if there is an immediate psychiatric crisis?

Someone experiencing acute suicidal danger, severe psychiatric instability or another urgent medical problem should receive appropriate immediate local assessment.

An overseas consultation or future admission is not a substitute for emergency care.

Family and caring responsibilities

Treatment may require arrangements for childcare, employment, transportation, communication and household responsibilities.

These practical matters can influence the feasibility of treatment and should be discussed before admission.

How can families provide useful support?

  • Encourage appropriate medical assessment without pressuring someone to stop prescribed medication.
  • Help compare available treatment services and understand financial terms.
  • Respect confidentiality and the patient’s right to participate in decisions.
  • Learn to recognise opioid overdose and how to use naloxone.
  • Provide practical support with appointments, transport and daily responsibilities.
  • Participate in family counselling when appropriate and agreed.
Example: Planning around parenting

A parent considering an overseas programme may need to arrange childcare, emergency contact arrangements and support for the period after returning home.

These issues should be resolved alongside the medical plan rather than after travel has been booked.

Back to top ↑
Section 9

Could DeBinge in The Bahamas Be an Option?

DeBinge describes a physician-supervised opioid treatment transition in Sandyport, Nassau, followed, when clinically appropriate, by a long-acting naltrexone implant and continuing counselling.

The programme may be of interest to selected adults considering antagonist-based recovery. However, eligibility cannot be established through promotional material alone.

Understanding the transition approach

DeBinge describes a supervised buprenorphine transition intended to manage the movement from opioid dependence toward naltrexone treatment.

The clinic states that patients do not need to complete a separate opioid-free waiting period before arrival for assessment and supervised transition.

This does not mean that the implant can safely be administered while clinically significant opioid dependence remains.

The treating team must determine readiness for naltrexone and assess individual risks.

What about people taking methadone?

Patients receiving methadone require particular consideration because changes to long-acting opioid medication can be complicated.

A short transition timetable must not be assumed to apply to every methadone patient.

What about the naltrexone implant?

The long-acting implant offered through DeBinge is not FDA-approved in the United States.

It is distinct from FDA-approved extended-release injectable naltrexone. The clinic should provide information about the exact formulation, clinical evidence, regulatory status in The Bahamas and potential complications.

Does the implant remove all cravings?

Naltrexone may help reduce cravings for some people and block opioid effects while clinically active, but it does not guarantee that cravings or relapse risk disappear.

Overdose remains possible, including when someone attempts to overcome blockade or returns to opioid use after tolerance has declined.

What should be confirmed before travelling?

  1. The proposed medical assessment and eligibility requirements.
  2. The treatment options and alternatives discussed.
  3. Clinical risks and possible complications.
  4. The responsible physician and nursing arrangements.
  5. Emergency care and hospital transfer procedures.
  6. Accommodation and travel requirements.
  7. Total price and cancellation terms.
  8. Medical follow-up and counselling after discharge.
No guarantee of suitability

A confidential consultation is an opportunity to explore eligibility, not a guarantee of admission, rapid transition, painless withdrawal or implantation.

Patients should not discontinue prescribed medication in preparation for travel without direction from their existing treating clinician.

Back to top ↑
Section 10

Costs, International Travel and Care After Returning Home

Request complete written pricing

Before paying for treatment, obtain a written quotation explaining what is included and excluded.

A previously discussed price of approximately $22,000 should be treated as indicative only until the clinic confirms its current programme fee.

What expenses should be checked?

Treatment-related costs

  • Medical assessment and tests
  • Prescribed medications
  • Nursing and physician care
  • Implantation procedure
  • Additional medical treatment
  • Emergency hospital services

Other practical costs

  • Flights and local transfers
  • Accommodation arrangements
  • Travel changes or delays
  • Additional nights if necessary
  • Follow-up appointments
  • Continuing medical care at home

What about insurance?

Coverage for international addiction treatment depends on the insurer and the specific policy.

Patients should not assume that a U.S. insurer will cover an overseas naltrexone implant, particularly a product that is not FDA-approved in the United States.

Ask about out-of-network treatment, overseas benefits, exclusions, advance authorisation and reimbursement requirements.

Plan aftercare before departure

A strong treatment plan should identify who will provide medical follow-up, counselling, urgent support and any continuing prescriptions or other services once the patient returns home.

DeBinge advertises ongoing counselling, but the current session schedule, provider arrangements and terms should be confirmed directly.

Example: A written financial and aftercare request

“Before making a financial commitment, please confirm the full treatment price, included services, additional charges, cancellation conditions and arrangements if implantation is delayed or deemed unsuitable.”

“Please also explain how counselling and medical follow-up will be coordinated after I return home.”

Back to top ↑
Patient and Family Guidance

Twenty Questions Patients and Families Should Ask

1. Why might someone struggle to get treatment?

Treatment providers differ in their medication policies, specialist staffing, capacity and admission criteria. Some residential programmes do not accommodate methadone or buprenorphine even though both are evidence-based treatments.

Other difficulties may involve medical instability, complex mental-health needs or administrative restrictions.

Practical guidance

Ask the provider to identify the specific reason for refusal and whether it can arrange a clinically appropriate referral.

2. Does this mean every clinic will turn them away?

No. Different services offer different levels of care. A refusal from one provider does not determine eligibility everywhere else.

Someone who cannot be admitted to a particular residential centre may still receive effective treatment through an opioid treatment programme, outpatient prescriber, hospital-based service or another specialist facility.

The next step is to identify a provider whose clinical capabilities match the patient’s needs.

3. Is this discrimination or a clinical capability issue?

The distinction depends on the circumstances. A provider may legitimately lack the resources for a particular medical situation. However, blanket medication exclusions or assumptions about people receiving treatment may raise questions under applicable laws and professional standards.

Request a written explanation and seek patient advocacy or legal advice if the decision appears discriminatory.

4. What should someone ask a clinic before applying?

Ask whether the facility accepts patients receiving methadone or buprenorphine, whether it has licensed prescribers, which withdrawal services it provides and how emergency situations are handled.

Also ask whether it can coordinate care with the patient’s existing treatment provider.

Example telephone question

“I currently receive prescribed medication for opioid use disorder. Can your programme accommodate that treatment, and what clinical assessment would be required before admission?”

5. What should happen during the first medical assessment?

The assessment should cover opioid and other substance exposure, current medications, physical health, psychiatric history, previous withdrawal experiences, immediate risks and treatment preferences.

The clinician should discuss suitable medication options and whether the proposed service can provide the required level of care.

6. Which treatments are supported by evidence?

Methadone and buprenorphine have strong evidence supporting their effectiveness for opioid use disorder and reducing overdose-related harms.

Naltrexone is also an established medication option for appropriately selected and safely inducted patients. Its suitability depends partly on the ability to complete the necessary transition.

7. Does everyone need to stop opioids before getting help?

No. People can receive assessment, support and treatment while physically dependent on opioids.

Methadone and buprenorphine can treat opioid use disorder without requiring a person to complete withdrawal first.

Naltrexone has separate initiation requirements because of the risk of precipitated withdrawal.

8. Can methadone or buprenorphine remain appropriate?

Yes. For many patients, long-term treatment with either medication is clinically appropriate and beneficial.

A person who has achieved stability should not be pressured to discontinue effective medication without a sound clinical reason and informed consent.

9. When might naltrexone be considered?

Naltrexone may be considered when an appropriately assessed patient prefers antagonist treatment, understands the alternatives and can undergo safe induction.

It may not be appropriate for someone who cannot safely complete the required transition or whose circumstances favour continued agonist treatment.

10. Why does medication history matter?

Different medications have different durations of action, interactions and withdrawal characteristics.

Methadone, buprenorphine, fentanyl and short-acting prescription opioids can present different clinical considerations.

Accurate information helps clinicians evaluate risk and establish an appropriate plan.

11. Can withdrawal be managed without unnecessary suffering?

Medical treatment can reduce distress and help manage complications. Methadone and buprenorphine are important options for many patients.

For those pursuing antagonist treatment, a supervised transition can include monitoring and symptom management, but a painless outcome must never be promised.

12. What can a private doctor contribute?

A physician can assess medical suitability, oversee the treatment plan, review medication interactions, monitor progress and respond to complications.

Patients should confirm the doctor’s credentials, responsibilities and availability throughout the programme.

13. What can dedicated nursing support contribute?

Qualified nursing staff can observe clinical changes, monitor symptoms, provide appropriate care and communicate concerns to the responsible physician.

Ask whether nursing support is continuous or provided during specified hours, especially overnight.

14. Does privacy improve the experience?

Privacy may help people discuss sensitive issues and feel more comfortable during treatment. Some patients also benefit from a quieter setting.

However, privacy is not the same as medical safety. Appropriate monitoring, emergency care and clinical expertise remain essential.

15. What mental-health support might be needed?

Patients may need support for anxiety, depression, trauma-related difficulties or other psychiatric conditions.

The appropriate programme should assess these concerns and explain when specialist psychiatric care or hospital services are necessary.

An immediate psychiatric emergency requires local urgent care rather than waiting for planned treatment abroad.

16. How should family or other responsibilities be planned for?

Before admission, arrange childcare, employment matters, transportation, finances and appropriate communication with trusted supporters.

Ask whether family counselling is available and how ongoing care will fit with the patient’s home responsibilities.

17. What are the risks of travelling for treatment?

International treatment involves potential delays, additional expenses, unfamiliar healthcare arrangements and the challenge of coordinating follow-up after returning home.

Clinical instability may make travel inappropriate. Patients should complete suitable screening and understand emergency plans before making arrangements.

18. What should a patient ask about the price?

Request a written breakdown of medical services, accommodation, medication, implantation, tests, counselling, additional treatment, travel costs and cancellation terms.

Ask what happens financially if the clinician determines that implantation cannot safely proceed.

19. What happens after the initial stay?

Recovery support should continue beyond the initial treatment period. This may include counselling, medical monitoring, mental-health treatment, medication management and relapse-prevention planning.

Before travelling, confirm who will provide these services, how appointments are arranged and what support exists if difficulties arise.

20. What is the safest next step today?

Arrange an assessment with an appropriately qualified addiction clinician. If you are already receiving methadone or buprenorphine, discuss any proposed changes with your existing prescriber.

If considering DeBinge, request a confidential suitability consultation, provide accurate medical information and ask for written details of risks, alternatives, costs and aftercare.

Immediate safety

If overdose is suspected, call emergency services immediately and administer naloxone if available. Follow emergency guidance and remain with the person until help arrives.

Back to top ↑
Practical Action Plan

Four Steps After a Treatment Refusal

1. Understand the Refusal

Request the specific reason and ask whether an alternative referral is available.

2. Protect Current Treatment

Continue coordinating prescribed medication with the existing clinician.

3. Compare Appropriate Services

Find providers offering the clinical capabilities and medication options needed.

4. Arrange Follow-Up

Confirm the assessment, ongoing treatment plan and emergency support.

Step 1: Obtain a clear explanation

Ask whether the refusal relates to medication policy, medical complexity, available staff, programme capacity or another requirement.

Step 2: Maintain continuity of medication

Do not make an abrupt medication change to gain admission. Speak with the existing prescriber about current treatment and any proposed alternatives.

Step 3: Contact an appropriate provider

Use recognised treatment locators, addiction specialists or referrals from your current clinician to identify services that match your needs.

Step 4: Confirm a practical plan

Before starting treatment, understand who is responsible for medical care, when follow-up will take place and how urgent problems will be managed.

Example: What to accomplish within the next day

Contact the original programme for clarification, ask your prescriber to review your options, identify another suitable provider and arrange an assessment.

If you are experiencing a medical emergency, seek immediate local medical assistance rather than following a routine appointment timetable.

Interactive Planning Tool

20-Question Treatment Access Self-Check

This questionnaire helps patients and families identify practical questions to discuss before applying to another treatment service or considering a medication transition.

Choose the answer that best reflects your preparation. At the end, you will receive a personalised list of topics to raise with a qualified professional.

The questionnaire is educational only. It does not determine medical eligibility, diagnose a condition or recommend stopping or switching medications.

Frequently Asked Questions

More Questions About Treatment Access and Medication Changes

Can a rehabilitation centre refuse someone because they take methadone?

Some programmes impose restrictions on methadone, but those rules do not mean that the medication is ineffective or that stopping it would be medically appropriate.

Applicable disability protections and other legal requirements may affect the permissibility of a particular exclusion. Patients can request the policy and seek professional advice where necessary.

Is taking buprenorphine considered successful recovery?

Yes. Buprenorphine is an evidence-based treatment for opioid use disorder. Continued medication can be an appropriate part of recovery and can support improved health and functioning.

Should I stop methadone to enter a residential programme?

Do not stop methadone simply to satisfy a facility’s admission rule without discussing the medical consequences with your prescribing clinician.

Ask whether the programme can coordinate with your provider or refer you to a service that supports your current treatment.

Can a person change from methadone to naltrexone?

A transition may be considered for selected patients under appropriately experienced clinical supervision.

It can involve significant withdrawal risk and must be individually assessed. It is not safe to assume that a short protocol will suit everyone.

Does everyone have to complete detoxification before treatment?

No. Methadone and buprenorphine can be used as ongoing treatments without completing a separate detoxification process first.

Naltrexone has different initiation requirements because it can precipitate withdrawal if given too early.

Can naltrexone be given while methadone remains active?

Introducing naltrexone while significant opioid dependence remains can cause severe precipitated withdrawal.

Only an appropriately qualified and experienced clinician should assess and manage a specialised transition.

Is the DeBinge implant approved by the FDA?

No. The long-acting implanted naltrexone formulation offered through DeBinge is not FDA-approved in the United States.

FDA-approved extended-release injectable naltrexone is a different product formulation.

Can a private clinic guarantee painless withdrawal?

No. Medical supervision can help manage symptoms and complications, but withdrawal experiences vary and no programme should guarantee a painless transition.

Will health insurance cover treatment in The Bahamas?

Coverage depends on the insurer, policy and proposed treatment. Patients should obtain written confirmation of any overseas benefits, exclusions and reimbursement conditions before making a financial commitment.

Where can I find another opioid treatment provider?

In the United States, FindTreatment.gov helps locate treatment services.

An existing clinician, licensed addiction specialist or local health service may also help arrange an appropriate referral.

Evidence and Resources

Clinical Sources and Further Reading

SAMHSA TIP 63

Comprehensive guidance covering methadone, buprenorphine, naltrexone and continuing treatment for opioid use disorder.

Read SAMHSA guidance

ASAM National Practice Guideline

Professional recommendations concerning opioid use disorder medications and treatment transitions.

Read ASAM guidance

SAMHSA: Buprenorphine

Patient and professional information about buprenorphine treatment.

Explore buprenorphine treatment

National Institute on Drug Abuse

Research concerning opioid use disorder, evidence-based treatment and overdose risks.

Visit NIDA

ADA and Opioid Use Disorder

Information about disability-related rights and discrimination involving opioid use disorder and prescribed medication treatment.

Read ADA guidance

FindTreatment.gov

Locate treatment services in the United States.

Find treatment
Confidential Consultation

A Treatment Refusal Should Not Be the End of Your Search for Help

If you are exploring opioid use disorder treatment or want to understand whether a supervised transition to antagonist-based care could be considered, request a confidential discussion with DeBinge.

The team can explain its programme and assessment process, but any treatment decision must depend on individual clinical suitability, informed consent and discussion of alternatives.

If you are currently receiving methadone or buprenorphine, do not change your prescription in preparation for a consultation or travel.

Request a Confidential Suitability Consultation

Medical disclaimer: This article is educational and does not replace medical advice. Medication transitions require qualified clinical supervision. DeBinge’s long-acting naltrexone implant is not FDA-approved in the United States. Provider-specific services, fees and treatment arrangements must be confirmed directly. Clinical review approved by Dr Fergus Law on 15 October 2026.

Categories: Treatment Options, Recovery & Healing
Tags: , , , ,
A confidential first conversation

Your next chapter
can start here.

Talk with our team about your situation, treatment suitability and travelling to Nassau.

Book a free consultation
Scroll to Top